Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE: 002399)
China
· Delayed Price · Currency is CNY 9.84
0.00 (0.00%)
Sep 9, 2024, 1:35 PM CST
Shenzhen Hepalink Pharmaceutical Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 5,494 | 5,384 | 7,097 | 6,318 | 5,284 | 4,570 | Upgrade
|
| Other Revenue | 76.08 | 61.79 | 61.92 | 47.33 | 48.04 | 54.68 | Upgrade
|
| Revenue | 5,570 | 5,446 | 7,159 | 6,365 | 5,332 | 4,625 | Upgrade
|
| Revenue Growth (YoY) | -8.89% | -23.94% | 12.48% | 19.38% | 15.30% | -3.95% | Upgrade
|
| Cost of Revenue | 4,584 | 4,501 | 4,861 | 4,367 | 3,300 | 2,947 | Upgrade
|
| Gross Profit | 985.69 | 944.92 | 2,298 | 1,998 | 2,032 | 1,677 | Upgrade
|
| Selling, General & Admin | 829.66 | 975.99 | 975.69 | 850.68 | 821.65 | 764.26 | Upgrade
|
| Research & Development | 168.11 | 182.43 | 252.14 | 221.1 | 160.01 | 148.71 | Upgrade
|
| Other Operating Expenses | 35 | 23.9 | 22.73 | 20.96 | 26.07 | 19.91 | Upgrade
|
| Operating Expenses | 1,021 | 1,183 | 1,299 | 1,165 | 1,018 | 930.52 | Upgrade
|
| Operating Income | -35.58 | -238.11 | 998.55 | 833.53 | 1,014 | 746.93 | Upgrade
|
| Interest Expense | -186.59 | -223.22 | -235.24 | -201.63 | -247.72 | -257.8 | Upgrade
|
| Interest & Investment Income | 444.76 | 39.52 | 54.14 | 54.86 | 301.79 | 656.92 | Upgrade
|
| Currency Exchange Gain (Loss) | -53.11 | 85.87 | 186.33 | -205.04 | -248.83 | 32.07 | Upgrade
|
| Other Non Operating Income (Expenses) | -32.58 | -37.31 | -32.55 | -46.18 | -30.47 | -23.64 | Upgrade
|
| EBT Excluding Unusual Items | 136.89 | -373.26 | 971.23 | 435.53 | 788.38 | 1,154 | Upgrade
|
| Impairment of Goodwill | -68.16 | -68.16 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -293.37 | -395.4 | -176.91 | -226.82 | 494.45 | 121.22 | Upgrade
|
| Gain (Loss) on Sale of Assets | -2.49 | -1.6 | -2.76 | -5.1 | 0.38 | 2.65 | Upgrade
|
| Asset Writedown | -45.22 | -45.22 | -0.42 | -1.1 | -0.24 | -0.44 | Upgrade
|
| Other Unusual Items | -56.07 | -44.7 | 38.71 | 19.75 | 44.87 | 37.03 | Upgrade
|
| Pretax Income | -328.41 | -928.33 | 829.85 | 222.26 | 1,328 | 1,315 | Upgrade
|
| Income Tax Expense | -66.72 | -126.17 | 114.82 | -11.12 | 306.2 | 271.38 | Upgrade
|
| Earnings From Continuing Operations | -261.69 | -802.16 | 715.04 | 233.38 | 1,022 | 1,044 | Upgrade
|
| Minority Interest in Earnings | 18.77 | 18.9 | 12.39 | 7.4 | 2.58 | 15.8 | Upgrade
|
| Net Income | -242.92 | -783.26 | 727.43 | 240.79 | 1,024 | 1,059 | Upgrade
|
| Net Income to Common | -242.92 | -783.26 | 727.43 | 240.79 | 1,024 | 1,059 | Upgrade
|
| Net Income Growth | - | - | 202.10% | -76.49% | -3.32% | 79.11% | Upgrade
|
| Shares Outstanding (Basic) | 1,468 | 1,467 | 1,468 | 1,467 | 1,353 | 1,247 | Upgrade
|
| Shares Outstanding (Diluted) | 1,468 | 1,467 | 1,468 | 1,467 | 1,353 | 1,247 | Upgrade
|
| Shares Change (YoY) | -0.01% | -0.05% | 0.05% | 8.42% | 8.51% | -0.01% | Upgrade
|
| EPS (Basic) | -0.17 | -0.53 | 0.50 | 0.16 | 0.76 | 0.85 | Upgrade
|
| EPS (Diluted) | -0.17 | -0.53 | 0.50 | 0.16 | 0.76 | 0.85 | Upgrade
|
| EPS Growth | - | - | 201.95% | -78.32% | -10.90% | 79.12% | Upgrade
|
| Free Cash Flow | 1,839 | -46.66 | -979.03 | -200.49 | -175.21 | -589.68 | Upgrade
|
| Free Cash Flow Per Share | 1.25 | -0.03 | -0.67 | -0.14 | -0.13 | -0.47 | Upgrade
|
| Dividend Per Share | - | - | 0.100 | 0.035 | 0.150 | 0.180 | Upgrade
|
| Dividend Growth | - | - | 185.71% | -76.67% | -16.67% | 80.00% | Upgrade
|
| Gross Margin | 17.70% | 17.35% | 32.10% | 31.39% | 38.11% | 36.27% | Upgrade
|
| Operating Margin | -0.64% | -4.37% | 13.95% | 13.10% | 19.01% | 16.15% | Upgrade
|
| Profit Margin | -4.36% | -14.38% | 10.16% | 3.78% | 19.21% | 22.91% | Upgrade
|
| Free Cash Flow Margin | 33.02% | -0.86% | -13.67% | -3.15% | -3.29% | -12.75% | Upgrade
|
| EBITDA | 282.45 | 85.48 | 1,272 | 1,103 | 1,287 | 1,003 | Upgrade
|
| EBITDA Margin | 5.07% | 1.57% | 17.77% | 17.34% | 24.14% | 21.68% | Upgrade
|
| D&A For EBITDA | 318.03 | 323.6 | 273.87 | 269.92 | 273.73 | 255.59 | Upgrade
|
| EBIT | -35.58 | -238.11 | 998.55 | 833.53 | 1,014 | 746.93 | Upgrade
|
| EBIT Margin | -0.64% | -4.37% | 13.95% | 13.10% | 19.01% | 16.15% | Upgrade
|
| Effective Tax Rate | - | - | 13.84% | - | 23.06% | 20.64% | Upgrade
|
| Revenue as Reported | 5,570 | 5,446 | 7,159 | 6,365 | 5,332 | 4,625 | Upgrade
|
| Advertising Expenses | - | 21.03 | 23.2 | 18.04 | 11.66 | 11.84 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.